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Study summary 
Background:  Despite remarkable progress in improving coverage of antiretroviral therapy (ART) in 
resource-constrained settings, early mortality among people with HIV starting ART remains high. 
Tuberculosis (TB) is the most important cause of death in people with HIV globally, including those 
starting ART. TB is common among individuals presenting to start ART in southern Africa, but existing 
diagnostic strategies perform poorly: the diagnostic pathway is slow, and many cases are missed. 
New TB diagnostics have potential to transform this situation. Urine lipoarabinomannan (LAM) 
antigen testing has high specificity and moderate sensitivity among HIV-positive individuals with 
advanced immunosuppression. This test is now available formulated for point-of-care use, at low 
cost, and could be used in primary care settings to identify TB among those at highest risk of both TB 
and of death. Haemoglobin and body mass index are also associated with risk of prevalent TB among 
people with HIV. 
 
Aim: To determine 6-month mortality among adults with HIV and CD4≤150, presenting for ART, 
managed using a point-of-care technology-based algorithm to rapidly identify individuals at high risk 
of TB and ensure they start TB treatment, then ART; and to compare this to 6-month mortality 
among adults managed according to standard practice based on South African guidelines. 
  
Methods: Open-label, pragmatic cluster-randomised trial, with primary health clinics as the unit of 
randomisation. Adults (at least 18 years) with CD4≤150 cells/µl who have not had TB treatment in 
the last 3 months will be eligible.  In intervention clinics, consenting adults will be assessed based on 
symptoms, urine LAM, haemoglobin concentration and body mass index. The study algorithm will 
use the results of these assessments to classify individuals as high, medium or low probability of TB. 
Those with high probability will start TB treatment immediately, followed by ART after 2 weeks. 
Those with medium probability of TB will follow the South African guidelines (sputum smear, chest 
radiography and trial of antibiotics) and will be reviewed after one week, to be re-categorised as low 
or high risk of TB.  Those categorised as low probability of TB will start ART as soon as possible. All 
participants in both arms will be followed up to 6 months. The primary outcome is all-cause 
mortality at 6 months. We will also explore the cost-effectiveness of this management strategy. 
 
Significance: If the study management strategy proves effective in reducing mortality, this algorithm 
could be implemented in resource-constrained settings and could substantially reduce early on-ART 
mortality. 
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1. Background 
  
The challenge of tuberculosis and HIV 
With an estimated 33.3 million people living with HIV in 2009, the management of HIV disease 
represents one of the most pressing challenges to global public health. Tuberculosis (TB) is the most 
important cause of death among people with HIV in resource-constrained settings,1 and the HIV 
epidemic is the main cause of the resurgence of TB over the last 30 years. Increasing access to 
antiretroviral therapy (ART) has dramatically improved survival, but individuals with advanced HIV 
disease continue to experience high mortality both while waiting to start2 and soon after starting 
ART,3 with TB a leading cause of death.2,4,5  
 
The problem of tuberculosis diagnosis in people with HIV 
Traditional diagnostic algorithms for TB, based on sputum smear microscopy, serve people with 
advanced HIV disease poorly, because smear microscopy has very low sensitivity, and for the 
majority of individuals whose sputum smears are negative, the diagnostic process is often 
protracted. Mycobacterial culture on automated liquid systems has better sensitivity than sputum 
smear but is expensive, prone to contamination, takes several weeks to give results, and laboratory 
capacity remains very limited in most settings of high HIV prevalence. Even where available, it is not 
clear that access to mycobacterial culture has a major impact on patient-relevant outcomes.6  
 
Tuberculosis among individuals presenting for ART in southern Africa  
In South Africa, 19-25% of individuals eligible to start ART have undiagnosed culture-positive 
tuberculosis.7,8 South African guidelines recommend a TB symptom screen at every HIV clinic visit, 
and 2 sputum specimens sent for smear and culture for TB suspects, but this is poorly implemented. 
In a retrospective review of a South African HIV programme, we found that 1524/4502 (33.9%) 
patients had two or more or cough, fever, night sweats or weight loss recorded, yet only 27/1524 
(1.8%) were documented to have had sputum samples sent.9  
 
In a separate prospective study in a South African clinic, we systematically screened individuals 
presenting to start ART for TB using symptoms, chest radiography and sputum culture (on liquid 
media). Only 9/350 (2.6%) were sputum smear positive, but 64/350 (18%) were culture positive for 
M. tuberculosis, and a total of 114/350 (32%) started TB treatment based on laboratory, clinical and 
radiological findings combined (Hanifa Y, personal communication, manuscript submitted). For 
individuals diagnosed by sputum culture, the median time from assessment to the start of TB 
treatment was 37 days. The median time from assessment to the start of ART, in this study where a 
full set of TB investigations were performed at enrolment, was 93 vs. 64 days for individuals with 
and without TB, respectively; in routine practice with investigations conducted sequentially, delays 
may be even longer. Most ART algorithms suggest that if TB is suspected, it should be ruled out, or 
diagnosed and treated, before ART is started. This is clearly desirable, to reduce TB case fatality and 
the risk of TB-immune reconstitution syndrome. However, in practice, this study shows that even 
when WHO-recommended diagnostic pathways are initiated promptly and correctly, patients 
experience long delays before starting treatment for either TB or ART or both, which may prove 
fatal.2  
 
In summary, limitations in existing TB diagnostic pathways result in two life-threatening problems for 
people presenting for ART; first, those who have active TB may be diagnosed and treated late, or not 
diagnosed or treated at all; second, the complex diagnostic pathway for smear negative TB results in 
considerable delay in ART initiation, both for those eventually diagnosed with TB, and also for those 
whose symptoms necessitate investigation, but are not diagnosed with TB.  
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New diagnostic tests for tuberculosis 
Genotypic detection systems allow more rapid identification of M. tuberculosis. Xpert MTB/RIF 
(GeneXpert, Cepheid) has potential to provide same-day results with greatly improved sensitivity 
over smear microscopy. It has excellent performance characteristics for smear-positive patients, but 
sensitivity was only 72% among smear-negative, culture-positive patients.10 HIV-positive individuals 
with low CD4 counts are often smear negative, and Xpert MTB/RIF will miss a substantial number of 
individuals in this group, who are at highest risk of death from TB. In addition, Xpert MTB/RIF is 
expensive, and unlikely to be widely available in primary health centres in resource-constrained 
settings in the near future.6  
 
There is thus an urgent need for management algorithms, using tools available at point-of-care in 
primary health care clinics, to identify individuals with advanced HIV disease who have a high 
probability of active TB, and of death from TB, in order that TB treatment can be initiated rapidly, 
followed by ART. 
 
Another newly-evaluated TB diagnostic test is an ELISA assay for lipoarabinomannan (LAM), a cell 
wall lipopolysaccharide specific to mycobacteria11 which is released from metabolically-active or 
degrading bacterial cells and is detectable in urine.12 A urine test is attractive because samples are 
easily collected and pose low infection risk to staff and other patients. Following evaluations of an 
early urinary LAM immunoassay13 and an analogous prototype test LAM-ELISA (Chemogen, South 
Portland, ME, USA) in sub-Saharan Africa and India,8,14-17  a commercial version marketed as 
Clearview TB ELISA (Inverness Medical Innovations Inc, Scarborough, ME, USA) has also been 
evaluated.18-20  Among HIV-negative patients, LAM assays are insufficiently sensitive, with a pooled 
sensitivity estimate of 14% in recent meta-analyses.21,22  Sensitivity is better, ranging from 21-81%, 
among HIV-positive TB patients.14,17-19,23 The wide variation in sensitivity between studies most likely 
reflects differences in methodology, study population and the gold standard for tuberculosis 
diagnosis. Sensitivity is consistently higher in patients with low CD4 counts19,22 (61% at CD4<50 cells 
per µl, 48% for all  <100, 44% for all <150, 36% for all <20023), probably because of higher 
mycobacterial load. Specificity of this assay is high irrespective of HIV status, and among HIV-positive 
patients ranges from 83-100%.8,17,19,20,23 Clearview TB ELISA detects both pulmonary and 
extrapulmonary TB,18 advantageous for HIV-positive patients.  
 
The Clearview TB ELISA assay provides results in less than 3 hours but is a laboratory-based test 
requiring urine processing within 24 hours (unless samples are frozen) which limits its utility in 
resource-constrained settings. A new point-of-care lateral-flow formulation of this test (Determine 
TB-LAM Ag [Alere, Waltham, MA, USA]) has recently been evaluated among ambulant patients 
screened for TB prior to starting ART in South Africa.23 Sensitivity was 27% overall vs. a gold standard 
of culture positivity, similar to sputum microscopy and to Clearview TB ELISA. Among hospitalised 
HIV-infected TB suspects, Determine® sensitivity was 74% in all TB cases, 85% among patients with 
CD4 count <100 cells per μL, and 75% in smear-negative culture-proven TB cases with CD4 count 
<200 cells per μL.24  Determine® TB provides results within 30 minutes, i.e. within a single clinic visit, 
and does not require refrigerated storage or sample processing. Inter-observer variability for reading 
the strips is good. 23,24 It is currently marketed in South Africa at $3.50 per strip and these 
preliminary evaluations suggest it has potential to be a useful low-cost point-of-care diagnostic test, 
particularly amongst patients with low CD4 cell counts.   
 
 
The performance characteristics of the urine LAM test are summarized in Table 1. 
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Table 1: Performance characteristics of urine LAM test 
Author,  
Country 
Type of test Patient characteristics (n) Sensitivity  Specificity  
HIV- HIV+ HIV- HIV+ 
Lawn23 
South Africa 
Determine® 
TB (POC)  
  
Clearview® 
TB-ELISA 
ART clinic enrollees with C+ 
TB (85) 
N/A Determine: 28.2% 
Clearview:  27.1% 
N/A  
ART clinic enrollees without 
TB (431) 
N/A N/A N/A Determine: 98.6%  
Clearview:  98.1% 
Peter 24  
South Africa 
Determine® 
TB (POC) 
     
Clearview® 
TB-ELISA 
Hospitalised TB suspects with 
TBa 
N/A 
Determine: 74% 
Clearview: 58% 
N/A N/A 
Hospitalised TB suspects 
without TB 
N/A N/A N/A 
Determine: 95% 
Clearview: 95% 
Gounder20 
South Africa 
Clearview® 
ELISA  
 
HIV-care attendees with 
microbiologically-proven TB 
(30) 
N/A 32% (SSM+ 40%, SSM- 
20%)   
N/A N/A 
Attendees without TB (392) N/A N/A N/A 98%  
Dheda19 
South Africa 
Clearview® 
ELISA 
Ambulant TB suspects with 
C+ TB (141) 
13% N/A N/A 
6% 21% (SSM- Cx+ 25%) N/A N/A 
Ambulant TB suspects with 
probable TB (127) 
2% N/A N/A 
Ambulant TB Suspects 
without TB (172) 
N/A N/A 
99% 
99% 100% 
Shah18 
South Africa 
Clearview® 
ELISA   
Hospitalized TB suspects with 
microbiologically confirmed 
TB (193) 
59% 
N/A N/A 
14% 67%  
Hospitalized TB suspects with 
possible TB (89) 
0% 18% N/A N/A 
Hospitalized TB suspects 
without TB (122) 
N/A N/A 
96% 
100% 94%  
Daley15 
India 
Chemogen 
LAM-ELISA  
TB suspects with Cx+ TB (47) 
17.8% (SSM+ 23%, SSM- 25%) N/A 
 20% N/A N/A 
TB suspects without TB (153) N/A N/A 
87.7% 
 83.3% 
Lawn8 
South Africa 
Chemogen 
LAM-ELISA  
ART clinic enrollees with C+ 
TB (58) 
N/A 38% N/A N/A 
ART clinic enrollees without 
TB (177) 
N/A N/A N/A 100%  
Mutetwa17  
Zimbabwe 
Chemogen 
LAM-ELISA  
Adult and adolescent C+ TB 
cases (161) 
44% (SSM+ Cx+ 50%, SSM- CX+ 28%) N/A N/A 
52%   21%   N/A N/A 
Probable TB cases (34) 27% N/A N/A 
Patients without TB (114) 
N/A N/A 89% 
93% 86% 
Reither16  
Tanzania 
Chemogen 
LAM-ELISA  
Ambulant TB suspects with 
C+ TB (69) 
50.7% (SSM+ 56.3%, SSM- 38.1%) 
N/A N/A 
21% 
62.0% (SSM+ 74.2%, 
SSM- 42%) 
Ambulant TB suspects without 
TB (82) 
N/A 
87.8% 
91% 84% 
Boehme14 
Tanzania 
Chemogen 
LAM-ELISA   
TB suspects with C+ TB (132) 
80.3% (SSM+ 82.9%, SSM- 76%) N/A N/A 
73.5% 81.2% N/A N/A 
TB suspects with probable TB 
(17) 
76.5% N/A N/A 
Healthy volunteers (103) N/A N/A 99.0% 
Tessema13  
Ethiopia 
In-house 
urine LAM  
Ambulant TB suspects with 
TBb (200) 
74% (SSM+ 81.3%, SSM- 57.4%) N/A N/A 
Ambulant TB suspects without 
TBb (800) 
N/A N/A 86.9% 
Healthy controls (50) N/A N/A 90% 
a Not all TB cases were culture-confirmed; bThe diagnostic work up for TB did not include mycobacterial culture.  POC, point of care; SSM-, sputum smear negative; 
SSM+, sputum smear positive; C+, Culture positive 
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A point-of-care algorithm for tuberculosis 
Other data which could identify individuals with a high probability of TB, and which could be 
available at the point of care, are haemoglobin (Hb) concentration and body mass index (BMI). Low 
haemoglobin and low BMI predict both prevalent TB among ART-eligible patients (Hanifa Y, personal 
communication, as above and table 2), and also early (<6 months) incident TB among patients 
starting ART (table 2).25 In addition, both low haemoglobin and low BMI are consistently associated 
with early mortality among people with HIV, including those starting ART.26-28 Additional analysis of 
South African data evaluating LAM among hospitalised patients18 suggests that among individuals 
with CD4<150, a tool comprising any of positive LAM, BMI<18.5 and Hb<10 has a sensitivity of 92% 
and positive predictive value of 54% vs. a gold standard of culture-positive TB (Shah M, personal 
communication). We propose to combine haemoglobin, BMI and urine LAM with symptom screening 
for TB29 to classify study patients as having high, medium or low probability of active TB (see Figure, 
Appendix 1), and accordingly start presumptive TB treatment, ART, or both, with minimal delay. An 
important strength of this algorithm is that we will identify individuals at highest risk of death (low 
Hb, low BMI and TB symptoms) and at highest risk of TB; by promptly starting appropriate therapy 
for these individuals, we will maximise the reduction in mortality.  
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Table 2: Baseline haemoglobin and BMI as predictors of prevalent and early (<6 months) incident 
TB among patients starting ART or attending for HIV care 
Author 
Country 
Study type 
Study population 
Study procedures 
Median CD4 count  
 (N) 
Association with prevalent TB + / or 
Association with early incident TB (< 6months) after ART initiation 
Baseline haemoglobin (g/dl) Baseline BMI (kg/m2) 
Van Rie25 
South Africa 
Observational cohort 
Adults initiating ART a  
ACF: at enrolment + follow-up 
  
 
(N=7536) 
<13 (m) / <12 (f) / <11 (pregnancy) 
vs. not anaemic 
aHR (95% CI)  incident TB b 2.54 
(1.92-3.37) 
< 18.5, 18.5-24.9, vs. ≥ 25 
aHR (95% CI)  incident TB b 2.03 
(1.34-3.07), and 1.69 (1.18-2.42) 
Lawn30 
South Africa 
Prospective study 
Adults enrolling for ART 
Systematic screening using 
sputum culture at enrolment 
171 cells/µl 
(N=468) 
 
< 18, >25, vs. 18-25 
aRR undiagnosed prevalent TB b  
2.94 (P=0.009) and 0.70 (P=0.24) 
Komati31 
South Africa 
Prospective trial  
Adults initiating ART a  
ACF: at enrolment + follow-up 
106 cells/µl 
 
(N=1771) 
Baseline BMI and haemoglobin significant risk factors for incident TB c 
(data not shown). 
Moore4 
Uganda 
Prospective cohort  
Adults initiating ART a 
ACF: at enrolment + follow-up 
127 cells/µl 
 
(N=1044) 
 
≤ 18 vs. > 18 
aOR undiagnosed prevalent TB d 
4.95 (P<0.001) 
Kufa T e 
South Africa 
Cross-sectional  
Patients attending for 
HIV care a 
Systematic screening using 
sputum culture at enrolment 
215 cells/µl 
(N=422) 
< 10 vs. ≥ 10 
aOR undiagnosed prevalent TB c  
3.12 (P=0.02) 
< 18.5 vs. ≥18.5  
aOR undiagnosed prevalent TB d  
2.70 (P=0.004) 
Hanifa Y e 
South Africa 
Prospective cohort 
Adults initiating ART a 
Systematic screening using 
sputum culture at enrolment 
120 cells/µl 
(N=293) 
 ≥ 10 vs. < 10  
aOR undiagnosed prevalent TB b  
0.32 (P=0.02) 
≥18.5 vs. < 18.5 
aOR undiagnosed prevalent TB b  
0.59 (P=0.12) 
 
aOR undiagnosed prevalent TB d  
0.53 (P=0.02) 
a Participants had not received isoniazid preventive therapy; b culture-proven TB; c microbiologically confirmed TB (smear 
or culture positive, any site); d TB cases included patients without microbiological confirmation;  e Personal communication, 
manuscript submitted 
ACF: active case finding for TB (clinical assessment followed by further investigation of TB suspects); aHR: adjusted hazard 
ratio; aOR: adjusted odds ratio; aRR: adjusted risk ratio; BMI: body mass index; CI: confidence interval; m: male; f: female  
 
 
 
Rationale for targeting individuals with CD4≤150 cells/µl 
We have selected the CD4 threshold of 150 cells/µl for the following reasons: 
(1) high risk for early mortality on ART 
(2) high risk for prevalent and incident TB disease 
(3) marked increase in mortality with delay in ART initiation with CD4 ≤ 150 
(4) relevant to many patients initiating ART in South Africa and other resource limited settings. 
 
Recently-published data from three randomized clinical trials are relevant to rapid ART initiation in 
this group, specifically in patients receiving treatment for TB.  The SAPIT,32 CAMELIA,33 and STRIDE34 
studies all reported decreased mortality among individuals who started ART within about 2 weeks of 
initiating TB treatment, compared with between 8 and 13 weeks of starting ART.  However, in the 
SAPIT and STRIDE studies this decrease in mortality was only observed among participants with 
baseline CD4 <50, and not those with CD4 50-500 or 50-200.  Sample size limited narrower CD4 
strata, thus the 25-35% of the patients in the higher CD4 category had CD4 >150.  Thus there are 
fewer data to guide the optimal timing of ART start among patients with CD4 > 50.  
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A further important point is the difference between those studies and the context of this proposed 
study.  In all three studies (SAPIT, CAMELIA and STRIDE), participants experienced mortality rates 
considerably lower than those we have observed in ART clinics in South Africa.  For example, the 
median CD4 count at entry into the CAMELIA study was 25, however, mortality was only 8 per 100 
person-years in the earlier ART arm vs. 13 per 100 person-years in the later ART arm.33  By contrast, 
in workplace and community setting ART care in South Africa,  mortality during the first 12 months 
of ART for individuals with CD4<50 ranges from 18-30 per 100 person-years.  It is unclear why the 
mortality in CAMELIA was so much lower than the overall South African experience, as the inclusion 
criteria did not specifically exclude particularly sick individuals.  However, one point about the 
inclusion criteria is worth noting: participants had to be sputum smear positive for acid-fast bacilli.  
As smear negative TB has a worse prognosis than smear positive,35-37 the individuals included in this 
trial may have been at lower risk of mortality.  The overall lower risk in mortality may have 
translated into a lower risk in overall mortality and a lower increase in mortality with ART delay.  The 
SAPIT study included patients with a wider CD4 range but all were required to be smear positive, 
thus also potentially selecting individuals with lower risk of dying.32  The STRIDE study included 
smear negative, TB culture positive patients, but excluded individuals with a haemoglobin ≤7 g/dl, 
absolute neutrophil count of ≤500, and platelets ≤ 50,000 thus (probably) eliminating individuals in 
most need of urgent cART initiation. 
   
Thus for the following reasons we believe that a CD4 threshold of ≤150 is appropriate for this study: 
(1) Lack of clear data from randomized clinical trials as to the optimal threshold for early ART 
among individuals starting TB therapy, particularly those who are sputum smear negative. 
(2) High mortality while waiting for ART and early on ART in the South African populations with 
which we have worked. 
 
Study hypothesis 
We hypothesise that a care pathway for adults with HIV presenting for ART with CD4≤150, using 
point-of-care technology to rapidly identify individuals at high risk of TB and ensure they start TB 
treatment, then ART, will markedly reduce early mortality. This will be via two mechanisms. Firstly, 
most people with active TB will initiate TB treatment rapidly and prior to ART, thus reducing TB-
specific mortality. Secondly, our strategy will reduce time to ART initiation among most individuals in 
the intervention arm, both with and without TB, which will reduce all-cause mortality. We 
hypothesise that the increase in survival due to this strategy will greatly outweigh the risks of 
treatment toxicities overall among individuals at high risk of early mortality presenting for ART. 
 
Systematic review for published studies addressing this issue  
We searched Medline and Embase using the terms 
1. (presumptive or empiric*) adj3 (treatment or therap*) 
2. AIDS or HIV or acquired immunodeficiency syndrome 
3. TB or tuberculosis 
4. 1 and 2 and 3 
We also searched "Africa wide information" using equivalent terms; and clinical trials databases. 
These searches yielded no studies of the type we propose. 
 
Other clinical trials addressing this issue  
ACTG A5274 (REMEMBER) is a multi-centre individually-randomised trial among individuals with 
CD4<50 and no evidence of definite or possible TB. The intervention comprises presumptive 4-drug 
TB treatment, started as soon as possible after (within 7 days of) the start of ART, compared to TB 
treatment given according to local practice (http://clinicaltrials.gov/ct2/show/NCT01380080). The 
trial is estimated to complete in August 2015.  
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PROMPT (http://clinicaltrials.gov/ct2/show/study/NCT01417988 ) is an individually-randomised trial 
in four African countries among individuals with CD4<50 and BMI<18, who are sputum smear 
negative and do not fulfil WHO criteria for smear negative TB. The intervention comprises 4-drug TB 
treatment, followed by ART within 2 weeks, compared with standard treatment with ART alone.  
This EDCTP-funded trial is estimated to complete in June 2014.  
 
Both these studies address the same problem as our trial, but using different approaches, and 
individually-randomised designs. At the time of writing (November 2011), neither has started 
recruitment. Our trial, with its innovative focus on accessible technology for point-of-care triage, will 
provide novel and complementary results, and will be particularly relevant to under-resourced 
primary care settings where chest radiography is not readily available. By evaluating this novel 
approach at clinic rather than individual level, we will be able to compare our strategy to the current 
TB diagnostic pathway as it is implemented in routine practice. 
 
Proposed study sites 
The Aurum Institute is funded by the President’s Emergency Plan for AIDS Relief (PEPFAR) to provide 
health systems strengthening support to primary health clinics in the Greater Tubatse and Ephraim 
Mogale subdistricts of Limpopo province.  This support consists of training, mentoring of nurses to 
initiate antiretroviral therapy, data management support and monitoring and evaluation.  In 
addition, the Aurum Institute provides HIV counselling and testing services in these districts and 
refers HIV-infected patients to the primary health centres.  Similar health systems strengthening is 
also provided by the Foundation for Professional Development in primary health clinics in the 
Tshwane district of Gauteng province and the Bojanala district of North West province.  Primary 
health clinics and health centres supported by Aurum and FPD are proposed as sites for this study, 
and a provisional list of clinics which may participate is shown below. We are currently in discussion 
with the relevant local health authorities concerning the participation of these clinics, and updating 
data concerning numbers of individuals initiating ART at each clinic in order to inform the final 
selection of clinics for this study. 
 
Table 3: potential study clinics 
DISTRICT SITE NAME ART ENROLLMENTS PER MONTH 
(mean over 3 months) 
GREATER TUBATSE PRAKTISEER 12 
GREATER TUBATSE BURGERSFORT CHC 33 
GREATER TUBATSE DILOKONG 44 
GREATER TUBATSE MECKLENBERG CCMT 22 
GREATER TUBATSE NGWAABE 8 
GREATER TUBATSE MAHUBEHUBE 8 
EPHRAIM MOGALE LEEWFONTEIN 13 
EPHRAIM MOGALE ELANDSKRAAL 10 
TSHWANE MARIA RONTO 30 
TSHWANE SOSH 2 33 
TSHWANE SOSH BLOCK TT 39 
TSHWANE SOSH CHC 70 
TSHWANE BLOCK X 34 
TSHWANE KGABO 79 
TSHWANE WINTERVELDT 20 
TSHWANE PHEDISONG 1 32 
TSHWANE PHEDISONG 4 35 
TSHWANE TLAMELONG 54 
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TSHWANE SHOSH BLOCK JJ 33 
TSHWANE KJ MOTUBATSE 70 
TSHWANE BOIKUTSONG 33 
TSHWANE GARANKUWA 16 
TSHWANE DR G MUKHARI 57 
TSHWANE ODI HOSP 54 
BOJANALA MATHIBESTAD 41 
BOJANALA MAUBANE 25 
BOJANALA SEAPARANKWE 16 
 
 
Potential risks to the trial: Xpert MTB/RIF roll-out 
A potential "risk" to the trial is the roll-out of new diagnostic tests for TB. In particular, Xpert 
MTB/RIF is being rolled out to laboratories in South Africa, and is under evaluation as a point-of-care 
test in primary health clinics in South Africa and elsewhere. Discussion with the South African 
Department of Health indicates that their top priority is to implement Xpert MTB/RIF within existing 
laboratories, before implementation in primary care centres. Preliminary costing data suggest that 
Xpert MTB/RIF costs will be highly sensitive to throughput, making it much more expensive to 
implement small Xpert instruments in clinics compared with larger instruments in laboratories. It is 
unlikely that Xpert MTB/RIF will be widely available in primary health centres, particularly in rural 
areas, during the timeframe of this study. In our final selection of study sites, we aim to avoid clinics 
likely to acquire this technology. Where Xpert MTB/RIF machines are placed in laboratories which 
are distant from the clinics they serve, the turn-around time is likely be similar to that for smear 
microscopy, which in our experience may be up to a week, and thus the availability of Xpert MTB/RIF 
is unlikely to reduce this turn-around time or the primary default rate (i.e. the proportion of 
individuals with a positive sputum result who never start TB treatment). In addition, Xpert MTB/RIF 
has relatively low sensitivity among individuals with advanced HIV-related immunosuppression (58% 
among individuals presenting to start ART in Cape Town30) and therefore, even if it can feasibly be 
used in rural primary health centres, it is not an ideal screening test in our target population.  
 
Our study will provide data which will complement studies evaluating Xpert MTB/RIF. Even if some 
participating clinics start to use Xpert MTB/RIF technology (on- or off-site), our study remains valid, 
and we will be able to document how implementation affects the diagnostic process and patient 
outcomes.    
 
 
2. Aims and objectives 
 
Primary objective  
To compare 6-month mortality among patients with HIV disease and CD4≤150 cells/µl referred to 
start ART between intervention clinics implementing a point-of-care algorithm to identify individuals 
with a high probability of active TB, and facilitate rapid initiation of TB treatment, followed by ART; 
vs. control clinics delivering standard of care management according to South African TB/HIV care 
guidelines. 
 
Secondary objectives:  
1. To compare severe morbidity in intervention vs. control arms, as measured by the duration of 
hospital admission in the first 6 months 
2. To compare time from enrolment to ART start in intervention vs. control arms 
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3. To compare overall retention in ART care, and retention among those known alive, at 6 months in 
intervention vs. control arms 
4. To document serious adverse events, and severe adverse events in specified categories, in the 
intervention and control arms   
5. To estimate the cost per disability-adjusted life year (DALY) gained 
 
Exploratory objectives 
1. To estimate the frequency of immune reconstitution syndrome in intervention vs. control arms  
2. To estimate mortality to 12 months in intervention and control arms 
 
 
3. Methods 
3.1 Study design  
Open (unblinded) pragmatic cluster-randomised trial, with primary health clinics as the unit of 
randomisation. 
 
3.2 Study sites 
The study will be conducted at primary health centres and community health centres in a mixture of 
urban and rural settings in Gauteng, North West and Limpopo provinces, South Africa, with which 
our teams already have working relationships.  
 
Inclusion criteria for participating clinics: 
 - capacity to initiate and deliver both TB treatment and ART 
 - rates of ART initiation which will allow us to recruit the required numbers (12 patients per month 
with CD4≤150 at each clinic) within the proposed timeline. 
 
Exclusion criteria for participating clinics:  
 - on-site mycobacterial laboratory facilities 
 - on-site Xpert MTB/RIF testing. 
Note added to protocol version 5.0, 31 August 2013: during the course of the study to date, Xpert 
MTB/RIF has been rolled out nationwide in South Africa, such that many of our study clinics are now 
using Xpert MTB/RIF as their first diagnostic test for people with HIV with symptoms suggesting TB. 
In this amendment we propose to expand the number of study clinics. Where possible, we will 
continue to avoid recruiting at any clinic where Xpert MTB/RIF is used with results delivered to 
patients on the same day, but we may include new clinics which use Xpert MTB/RIF routinely for HIV 
positive people. 
 
3.2.1 Randomisation of study clinics 
Clinics will be randomly allocated to intervention or control arms.  Since site assessment data 
showed little variability in the proportion of patients potentially eligible for the study with CD4<50, 
the random allocation will not be stratified. Randomisation will be restricted based on urban/rural 
(which also provides restriction by province since all urban clinics are in Gauteng province), mean 
CD4 at ART initiation,  and total number of patients initiating ART per month, in order to help 
achieve overall balance between the study arms. The senior statistician will be responsible for the 
randomisation. 
 
Note added to protocol version 5.0, 31 August 2013: we propose to extend enrolment to four 
additional clinics in order to ensure that the study remains adequately powered to detect an 
important difference in mortality between arms, assuming that four additional clinics can be found 
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where recruitment is predicted to be rapid, in order to minimise the impact on study timelines.These 
four clinics will be randomised in a ratio of 1:1 to the intervention and control arms. 
 
3.3 Study population 
The study population comprises adults with HIV infection, with CD4≤150 cells/µl, and willing to start 
ART. In order to maximise generalisability, we plan to make the trial as inclusive as possible. 
 
3.3.1 Patient selection criteria 
Inclusion criteria:  
 - documented HIV seropositive status; 
 - eligible and willing to start ART; 
 - CD4≤150 cells/µl. 
 
Exclusion criteria: 
 - age <18 years; 
 - currently on TB treatment, or completed TB treatment in last 3 months; 
 - any ART taken in the last 6 months; 
  
 - contraindication to efavirenz (based on current South African ART guidelines); 
 - too sick to be managed in ambulatory care; 
 - other symptoms necessitating immediate referral to secondary care; 
 - known chronic hepatitis or high alcohol intake (per week, >28 units (men) or >21 units (women) 
 - intending to move away from the study clinic area in the next 6 months. 
 
 
3.4 Patient selection procedures 
Consecutive patients referred (either internally within the clinic or from another facility) for ART 
initiation who have CD4≤150 cells/µl will be referred by health service staff, with the patient's 
agreement, to study staff for explanation of the study, and enrolment if they are eligible and give 
consent.  A log will be kept of patients who refuse referral to the study team or are not enrolled, for 
whatever reason. 
 
3.5 Intervention 
The intervention comprises a management strategy which aims to identify, among HIV-positive 
patients with CD4≤150 cells/µl, presenting to start ART, those at highest risk of TB, so that they can 
start TB treatment immediately, followed by ART.  
 
After a consenting patient has been determined to be eligible to join the study, the study nurse will 
complete a questionnaire to determine TB symptoms (cough, fever, weight loss, night sweats), TB 
history and WHO stage. The nurse will then determine the BMI, perform a point-of-care urine LAM 
assay, and, if no haemoglobin result is available, determine haemoglobin concentration using a 
point-of-care assay.  
 
The study algorithm is illustrated in the Figure (appendix 1). Patients with any of: positive LAM, 
Hb<10 g/dl, BMI<18.5 (along with any patient known to be sputum smear positive, or Xpert MTB/RIF 
positive) will be categorised as high probability TB, and will start TB treatment immediately. The 
algorithm is applicable regardless of whether the suspected TB is pulmonary or extrapulmonary. In 
line with WHO and South African guidelines, they will start ART as soon as possible (usually two 
weeks) afterwards. Patients who have no symptoms suggesting TB, negative LAM, Hb≥10 g/dl and 
BMI≥18.5 (and not known sputum smear positive) will be categorised as low probability TB, and will 
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start ART (without TB treatment) as soon as possible. All others (symptomatic but negative LAM, 
Hb≥10 g/dl, BMI≥18.5) will be categorised as medium probability TB, and will be managed in 
accordance with national guidelines for smear-negative TB, i.e. given broad spectrum (non-
quinolone) antibiotics if indicated; an additional routine sputum sample will be taken for smear and 
mycobacterial culture in line with routine practice, and chest radiography will be arranged if not 
recently performed, with review within one week wherever possible. At review, they will be 
classified as high or low probability of TB, based on symptom review, response to antibiotic 
treatment, sputum smears, chest radiograph report, and repeat urine LAM. Those with high TB 
probability will start TB treatment, then ART as soon as possible; those with low TB probability will 
start ART as soon as possible. Patients with specific symptoms suggesting diagnoses other than TB 
will be managed in accordance with national guidelines.  
 
Patients in intervention clinics who start TB treatment based on the study algorithm will, when they 
start ART, need to take efavirenz-based ART in order for their ART to be compatible with TB 
treatment, and any unable or unwilling to do so will be excluded from the trial.  Outside this 
situation, patients can take any ART regimen appropriate for them, as specified in South African ART 
guidelines.  
 
 
3.6 Outcome measures 
Primary outcome:  
All-cause mortality at 6 months after enrolment 
 
Secondary outcomes:  
1. Duration of hospital admission in first 6 months after enrolment 
2. Time from enrolment to ART start 
3. Proportion of patients retained in care, i.e. documented to have attended clinic for HIV care at 6 
months (window: 150-240 days) after enrolment 
4. Study-defined serious adverse events, and severe adverse events in specified categories 
(particularly hepatotoxicity, hypersensitivity, peripheral neuropathy, and nephrotoxicity) 
5. Economic outcomes, detailed below 
 
We explain above our rationale for defining mortality as the primary outcome; we will assess this at 
6 months because the risk of death reduces substantially with increasing time after ART start. It is 
possible that there may be increased morbidity in the intervention arm as a result of drug toxicity or 
immune reconstitution syndrome. A secondary outcome is therefore severe morbidity, defined by 
duration of hospitalisation (determined by patient report supplemented by notes review). We will 
compare time to ART start and retention in care to 6 months between study arms. To assure patient 
safety, we will report study-defined serious adverse events, and severe adverse events in specified 
categories. 
 
 
3.7 Study procedures 
 
3.7.1 Enrolment procedures: intervention and control clinics 
Participants will be enrolled at the time they are determined eligible to start ART. 
At enrolment, following informed consent, participants will complete a questionnaire covering  
 - locator information, including national ID number 
 - demographic information 
 - past history of TB, HIV (including date of HIV tests and previous ART exposure) and other illnesses 
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 - TB symptoms (using WHO screening tool, also including symptom duration) 
 - height and weight (for BMI) 
- most recent CD4, from clinic notes  
 - haemoglobin, from clinic notes 
 - any TB test results, from clinic notes 
 
Participants in both intervention and control clinics will also be asked to give: 
i) a urine specimen for storage for study purposes: this will be tested at a later date for tuberculosis,  
and for LAM using the lateral flow or laboratory ELISA assay. We may also perform laboratory tests 
for evidence of other relevant conditions such as cryptococcal disease and pneumococcal disease. 
ii) a finger-prick blood sample to be stored as  around 3 dried blood spots, which will be tested later 
for evidence of relevant conditions such as cryptococcal disease or hepatitis B infection. 
These specimens will be transported to BARC laboratories, Johannesburg, and stored for later 
testing in batches; results will not be returned to clinics and will not be available for patient 
management. Any specimens remaining after these tests have been performed at BARC will be 
transferred to the Aurum Institute laboratories, Johannesburg, and stored for up to five years after 
the end of the study, in case tests become available which can be performed on urine or dried blood 
spots which help us understand causes of disease in our study participants. If we propose to do any 
tests which are not listed above, we will seek additional approval from Research Ethics Committees. 
 
3.7.2 Clinical pathway in intervention clinics 
In intervention clinics, a research nurse will assess patients at enrolment, determine their BMI, 
haemoglobin, perform a point-of-care urine LAM test, and facilitate their treatment pathway based 
on the study algorithm (appendix 1). Patients assigned by the algorithm to start TB treatment will be 
managed in accordance with national guidelines. Research staff will promote treatment literacy and 
adherence to both TB treatment and ART, to offset the anticipated increased burden on routine TB 
services because of higher numbers of patients on TB treatment as the study rolls out (ART 
treatment support is standard of care in South Africa). It is possible that retention in care could be 
lower in the intervention arm because patients will start treatment sooner, with less delay to allow 
pre-ART counselling. Retention in care is thus is a secondary outcome of the study. 
 
A sputum sample will be taken from all intervention arm participants at enrolment for study 
purposes, to allow determination of a "gold standard" TB diagnosis (defined as culture positive for 
M. tuberculosis). If the study sputum sample taken at enrolment yields positive results on culture or 
drug susceptibility testing (DST) (based on the MTB DR Plus or other assay), these results will be 
communicated to the clinic so that patients' treatment can be modified accordingly.  
 
Symptomatic enrolees will have a sputum sent for smear (or Xpert MTB/RIF) via the routine system 
operating in their clinic, in accordance with national guidelines.  
 
Study staff will endeavour to ensure that study participants are managed in accordance with the 
study management algorithm. However, since participants remain under the care of clinic staff 
throughout the study, if a clinic doctor considers that a participant’s management should differ from 
the pathway proposed by the study algorithm, their opinion will be respected. Such decisions will be 
documented by study staff in order that adherence to the study algorithm can be determined.  
 
3.7.3 Procedures in control clinics 
In control clinics, we will similarly recruit HIV-positive patients with CD4≤150 at the point they 
receive their CD4 result. Consenting patients will similarly be interviewed by a study nurse 
concerning locator information, complete the baseline questionnaire, and have BMI determined. No 
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further study procedures are required, and further assessment for TB and preparation for ART will 
be undertaken by clinic staff according to routine practice following national guidelines: 
symptomatic patients submit sputum for microscopy; TB treatment is started if the sputum smear 
(or Xpert MTB/RIF) is positive; and further investigations with sputum culture and chest radiography 
will be undertaken if the sputum smear is negative.  
 
At all clinics taking part in the study, whether assigned to intervention or control arm, if 
management guidelines for TB suspects change during the study period (for example if Xpert 
MTB/RIF becomes standard of care in any study clinic) then TB suspects will be managed according 
to the updated guidelines. Senior clinically-qualified investigators on the study team will be available 
to discuss clinical management of study participants if clinic staff have uncertainties or concerns. 
 
Study procedures are summarised in Table 4. 
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Table 4: summary of study procedures 
 
  INTERVENTION CLINICS CONTROL CLINICS 
 Enrolment 1 week 
(or less) 
2 weeks 2 months 6 months Enrolment 1 week 
(or less) 
2 months 6 months 
Informed consent √     √    
          
Locator information √     √    
Baseline questionnaire √     √    
TB symptom screen √ √*    √    
BMI √     √    
Lab tests          
      Haemoglobin √         
      Urine LAM √ √*        
      Sputum TB microscopy    
& culture 
√         
Urine / dried blood spot 
for storage 
√     √    
TB patient follow up visit   √**       
Patient record review  √  √ √  √ √ √ 
6 month questionnaire     √    √ 
12 month questionnaire 
(subset of participants) 
     √    √ 
 
 
* For those with medium probability of TB according to the study algorithm 
** For those started on TB treatment, to check if stable on TB treatment and ready to start ART 
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3.7.4 Follow up procedures 
Patients in the intervention arm who are classified by the algorithm as medium probability TB will be 
reviewed by study staff within one week wherever possible. At this visit, if there is evidence of 
tuberculosis based on continuing symptoms, non-response to antibiotics, positive sputum smear, 
positive Xpert MTB/RIF result, mycobacterial culture, radiographic evidence or urine LAM, they will 
start TB treatment. If they are asymptomatic and have no other evidence to suggest active TB, they 
will start ART. If there is uncertainty, clinical judgement will be used, in discussion with clinic staff 
and if necessary study clinicians.  
 
Patients in the intervention arm who start TB treatment will be reviewed by study staff around two 
weeks later, to facilitate the start of ART if there is no clinical reason to defer the start of ART. 
 
Subsequent management of patients in both arms will be primarily by clinic staff, following South 
African guidelines. If there are uncertainties or concerns, particularly concerning patients in the 
intervention arm who start TB treatment on the basis of the study algorithm alone without other 
supporting evidence, clinic staff will be encouraged to discuss management with study clinicians, one 
of whom will be available at all times. It may be appropriate for some patients to discontinue TB 
treatment if there is no supporting evidence and no evidence of improvement. Such decisions will be 
made by clinic staff, supported by study staff as required, and referral to higher level care for 
additional investigation and treatment may be needed. 
 
Clinic records of all patients in both arms will be reviewed after about one week, to capture routinely 
sent pre-ART baseline blood tests (haemoglobin, liver function tests, creatinine etc), and again at 
about 2 months, to determine TB treatment start date; progress on TB treatment; any adverse 
events on TB treatment; ART start date; any adverse events on ART; laboratory results since 
enrolment (particularly any sputum smear or culture results, CD4 counts etc) and reports of any 
other investigations, such as radiology; treatment given, health service use including number and 
nature of clinic visits, and referrals to other services. If this record review uncovers any positive 
results, particularly positive TB microbiological results, which have not been appropriately acted 
upon, study clinicians will be consulted and the clinical team informed if it appears that the patient's 
management should be reviewed. 
 
All patients in both arms will be reviewed 6 months after enrolment, wherever possible by face-to-
face interview, to determine health status, treatments received and health service use (e.g. number 
and type of clinic visits; duration and nature of any hospitalisation) since enrolment. This 
information will be supplemented by review of clinic records, similarly to determine use of health 
services, (particularly any hospitalisation), any additional diagnoses made and adverse events 
documented, and treatment given. For patients who have been hospitalised, hospital records will be 
reviewed to determine duration of hospitalisation, level of care given and proposed diagnoses. The 
interview will include questions relevant to the economic outcomes described in section 4. 
 
A subset of participants recruited in the early phase of the study will be asked for permission for 
extended follow-up to 12 months, to determine vital status and major morbidity, particularly any 
new TB episodes. A short interview will be undertaken at 12 months either in person, preferably to 
coincide with a clinic visit, or by telephone if this is more convenient. 
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3.8 Pilot study work 
All case report forms will be piloted in an anonymised fashion i.e. collecting data without any 
personal identifiers, in order to ensure that the forms are acceptable to, and easily comprehensible 
by, participants, that they fulfil their purpose well, and to test study systems. These data will not 
contribute to the final analysis. 
 
To help the study team understand current practice and patient pathways in the study clinics, we 
will collect anonymised data from routine records to document usual practice for management of 
patients with HIV presenting to start ART before the start of the intervention. This will involve only 
record review: no patient contact will be required. If feasible, we will collect data on 50-100 patients 
per clinic. This will include time from first HIV positive test to CD4 result being given; among those 
eligible to start ART, TB screening practice and time from CD4 result to start of ART; 6-month 
outcomes on ART; TB treatment outcomes among patients with HIV. We will also review TB and ART 
treatment records to collect anonymised information from a sample of patients at each clinic 
concerning health service use (number and nature of clinic visits; any hospital referrals and / or 
hospitalisations) and records of adverse events or symptoms suggesting immune reconstitution 
syndrome, in order to refine and pilot test our case note extraction procedures. 
 
The validity of the study will depend on successful follow-up of a high proportion of participants, 
with accurate ascertainment of outcomes. We will therefore specifically test these procedures on 
around 10-20 patients per clinic (both intervention and control); however, no study tests (LAM or 
haemoglobin) will be performed as part of this pilot study, and patient management will be as per 
usual practice. We will collect data at enrolment as for control clinics, with follow up to around 2 
months (timed to coincide with a routine clinic visit). At follow-up, we will seek information on vital 
status, diagnoses since enrolment, treatments and health care use, based on interview of the 
patient, or if they are not contactable, their designated contacts, and review of medical records. In 
addition we will seek feedback from participants concerning their experience, in order to refine our 
procedures for the main study. A specific participant information sheet will be used for this pilot 
phase.  
  
 
3.9 Ascertainment of outcomes 
All study patients will be reviewed 6 months after enrolment to determine primary (vital status) and 
secondary outcomes as above (plus retention in care at 6 months), based both on patient interview 
and on medical records. Study patients will be actively traced, if necessary, using locator information 
obtained at enrolment. Study patients who cannot be traced will be matched against South African 
mortality registration using their national ID number. In addition, to minimise ascertainment bias, a 
record review will be conducted for all study patients (intervention and control arm) after 2 months 
to document vital status, and any secondary outcomes (ART start date, TB treatment start date, 
documented symptoms suggesting immune reconstitution syndrome, documented health service 
use including hospitalisations etc). 
 
As part of routine care, clinic staff should ensure that patients' contact details are up to date at every 
attendance. As part of routine support to the participating clinics, during the study period, Aurum 
and FPD programme staff will work with clinic staff to strengthen these existing systems for TB and 
HIV patients. This will assist study staff with tracing of any participants who are lost to follow up, but 
will be of benefit to staff and TB/HIV patients at all participating sites, regardless of study arm. 
TB Fast Track: protocol version 6.2  8 July 2015     Page 22 of 40 
 
 
3.9.1 Definition of adverse events 
All drugs used in this study are licensed drugs, used for their licensed indications. The purpose of 
adverse event reporting in this study is not to identify potential new adverse events associated with 
drugs used in the study, but rather to ensure that the study management strategy does not cause 
harm to participants. We therefore do not propose to report all adverse events, but to report serious 
and severe adverse events in study-defined criteria.  
 
A serious adverse event will be defined, conventionally, as one which:  
o results in death 
o is life-threatening (defined as an event in which the patient was at risk of death at the time 
of the event; it does include an event which hypothetically might have caused death if it 
were more severe) 
o requires inpatient hospitalization or prolongation of existing hospitalization (hospitalisation 
is defined as an inpatient admission, regardless of length of stay, even if the hospitalisation 
is a precautionary measure for continued observation.  Hospitalisations for a pre-existing 
condition, including elective procedures that have not worsened, do not constitute an SAE) 
or  
o results in persistent or significant disability/incapacity 
AND is in one or more of the study-defined categories of hepatitis, hypersensitivity, peripheral 
neuropathy, optic neuritis or nephrotoxicity.  
 
We will also report severe adverse events, defined as those graded 3 or 4 using the Division of AIDS 
classification (appendix 2), in the study-defined categories. We will report all deaths in either study 
arm, regardless of cause.  
 
3.9.2 Ascertainment of adverse events 
Data sources for ascertainment of adverse events include: 
 - participant interview at the 6 month visit 
 - if the participant cannot be contacted at 6 months, reports from friends and / or relatives 
 - participant medical records and patient registers, reviewed systematically at 2 and 6 months after 
enrolment. 
 
Given the additional study visits early after enrolment for intervention arm participants categorised 
to high or medium probability, we anticipate that ascertainment of adverse events is likely to be 
much higher in the intervention arm. We will document the method of ascertainment for possible 
adverse events so that we can compare those ascertained in a similar way (i.e. based on case note 
review and 6 month interview) in the two arms. However, we expect that in the intervention arm, 
events are more likely to be recorded in routine case notes, as a consequence of study activities. The 
frequency of adverse events compared between study arms will need to be interpreted with these 
issues in mind.  
 
3.9.3 Management of adverse events 
Since all the drugs used in this study are licensed drugs being used for licensed indications, 
management of suspected drug-related adverse events will be according to national and local clinic 
guidelines.  
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3.10 Barriers to implementation: a sub-study among health care 
workers 
If the intervention has a positive effect, we will motivate for its implementation. In anticipation of 
this, we would like to learn from the experience of staff involved with delivering the intervention, to 
identify potential barriers to implementation.  
 
We propose to interview clinic and study staff primarily in intervention clinics. The clinics will be 
purposively sampled to include urban and rural sites, and high and low case-load clinics. The main 
focus will be on intervention clinics but we might include control clinics if necessary for comparison.  
 
Staff to be interviewed will be selected on a clinic by clinic basis (since clinics are staffed differently, 
and key personnel will vary by clinic) and may include clinic doctors and nurses; study nurses and co-
ordinators; and more senior personnel such as clinic facility managers, HAST managers and TB co-
ordinators.  
 
The interviews will be conducted by a Masters' level student, supervised by the investigators. The 
MSc student will not have had previous involvement in the study and thus may be seen by 
interviewees as distinct from the study team (although we recognise that social desirability bias is 
still likely to influence responses). Interviews will include both closed and open questions (see 
interview guide, provided as a separate document) and may be tape recorded if the participant gives 
consent.  All paper and soft copies of field notes, audio files, consent forms and any other notes will 
be kept securely and if in digital format will be on a password protected computer, backed up 
regularly. The content of discussions and interviews will not be revealed to anyone other than 
authorized study staff, investigators, and monitors. All information collected during the course of 
this study will be kept securely and confidentially in a locked cupboard for at least five years after 
the study is finished. 
 
A coding template will be developed from a few of the early transcripts, and will be used to code 
later transcripts. Each line, or few lines, will be coded and labelled according to the idea(s) in the 
transcript, using a short title, and used to create a new tree node. As coding develops and themes 
emerge, nodes will be arranged in groups under a parent node labelled with the theme. Descriptive 
statistical analysis will be performed on demographic and other quantitative data in Excel, Epi-Info 
or Stata. 
 
Written informed consent will be sought from potential participants using standardised 
information sheets and consent forms, provided as a separate document. 
 
3.11 Time to ART start post trial: a sub-study 
Addition to protocol v 6.2, 8 July 2015 
The presence of research teams in study clinics has the potential to influence routine clinic practices 
with respect to important processes such as time to ART start. In addition, South African national 
guidelines concerning the management of TB and HIV have changed since the trial was 
conceptualised. In particular, Xpert MTB/RIF has become the universal first line investigation for TB 
(as anticipated), and individuals with CD4 counts below 200 cells/µl should now be “fast tracked” to 
start ART.  In order to better understand how these policy changes have affected relevant aspects of 
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patient management in the trial clinics over the calendar period of the trial, we propose to repeat 
the retrospective pilot study outlined in section 3.8.  
In all clinics which took part in the trial, we will collect anonymised data from routine records to 
document usual practice for management of patients with HIV presenting to start ART. This will 
involve only record review: no patient contact will be required. We aim to collect data for a 
consecutive sample of around 50 patients per clinic, starting after trial recruitment was complete. 
Key data include time from first HIV positive test to CD4 result being given; among those eligible to 
start ART, TB screening practice and time from CD4 result to start of ART; 6-month outcomes on 
ART; TB treatment outcomes among patients with HIV.  
 
Research staff will collect these data on standardised case report forms that will later be entered 
into a customised database.  
 
These data will help us understand whether and how TB investigation practice and time to ART start 
has changed over the period of the study. The results will be important in enabling us to understand 
and interpret our trial results. 
 
4 Economic analyses 
Demonstration of affordability and cost-effectiveness will be essential in making a case for 
implementation of our management strategy, should it prove effective. We will estimate the 
following economic outcomes: 
 
 diagnostic cost per TB suspect 
 total diagnostic cost of the study cohort in intervention and control arms 
 cost per month of TB treatment (intensive and continuation phase) 
 cost per month of ART 
 episode costs of treating relevant opportunistic infections 
 total TB and HIV care and treatment cost of the study cohort, per patient, in intervention and 
control arms 
 incremental diagnostic cost of intervention compared to control 
 incremental treatment cost of intervention compared to control 
 incremental cost per DALY, taking into account: 
o costs of i) diagnosis and ii) treatment  
o cost savings from reduced hospitalisations during the study period 
o DALYs averted from morbidity associated with opportunistic infection episodes and 
deaths averted during the study period 
 
The economic evaluation will be conducted using a health service perspective, conservatively 
assuming no broader societal costs. All costs of TB suspect identification, TB diagnosis and 
treatment, and HIV care and treatment given during the period of follow-up will be estimated. Given 
the complexity of diagnosis and treatment pathways in each arm, we will estimate health service 
costs by combining the unit cost of each procedure along the diagnostic and treatment pathway 
across all study sites, with the probabilities of following each pathway for each study arm cohort.  
These probabilities will be derived from health service record review and the follow-up interview at 
six months. The aim will be to identify treatment-related health service use, and any major events 
such as hospitalisation. 
 
The unit cost of each procedure will be measured using an ingredients approach, based on financial 
records and directly observed resource use. This will include the collection of data on staff time use, 
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based on a mixture of observation and time sheet reporting. Staff will be asked questions about the 
time they spend on each different procedure related to TB/HIV diagnosis, treatment and care. They 
will also be observed carrying out patient consultations to measure the time that each consultation 
takes. Time use will then be combined with salary costs to estimate the personnel cost associated 
with each procedure. Time use data will also be used to assign overhead costs.  
 
We will cost diagnostic procedures at all study sites to ensure a full range of costs is captured. 
Treatment costs will be estimated from a stratified sample of sites (based on location, size and 
patient load). We may also refer to other costing studies where treatment is provided outside the 
study sites (such as hospitalisation). Diagnostic costs will be collected 2 months and 5 months after 
the start of the study to estimate both start up and routine costs. Treatment costs will be collected 
from month 3 after the start of the study and will be considered routine. 
  
We will estimate DALYs averted from trial outcomes on mortality and morbidity. We do not propose 
to include quality of life measures, and will used standard DALY disease weightings for morbidity 
during the study period. We will conservatively assume no beneficial health effects from the 
intervention after the study period, since most deaths occur in the first few months on ART.  
As we have no prior knowledge of the costs (particularly of averted hospitalisation) in the 
intervention arm, we have not powered the trial to establish differences in cost-effectiveness. 
Instead, we will address any uncertainty due to low power using probabilistic and a range of one- 
and two-way sensitivity analyses, presenting acceptability curves where relevant.  
 
4.1 Patient costs: an exploratory sub-study 
The intervention might be anticipated to reduce patient costs overall. The costs to patients of being 
treated for TB are reported to be very high, but few data are available concerning costs incurred by 
patients as a result of investigation for TB before starting ART.  In a sub-study, we propose to identify 
and explore the affordability, indirect costs and catastrophic spending, by individuals and families, 
among participants in the TB Fast Track study.  
 
Participants in the TB Fast Track study who are attending the clinic for a 6-month visit will be invited 
to take part in this sub-study. A purposive sampling strategy will be used to gather data e.g. from 
people with fewer socioeconomic resources, and contrasting those in urban vs. rural settings. We 
will aim to interview around 50 participants in urban/ peri-urban clinics and around 50 in rural 
clinics.  We will explore differences between people in the intervention and control arms, but, due to 
limited staff resources, this sub-study is likely to have limited power for a formal comparison 
between study arms. If resource permit the study may be extended to a larger number of 
participants. 
 
Direct and indirect costs to be assessed will include costs incurred attending out-patient visits; costs 
of any hospitalisation; costs of complementary care; costs incurred by carers; costs due to loss of 
employment; reduced household activities; decreased productivity; coping strategies. 
A draft questionnaire is supplied.  
 
In order to reduce the length of the interview and to reduce any repetition, participants will be 
asked also for permission to use for this sub-study data previously provided as part of the main TB 
Fast Track study. 
 
Quantitative data will be analysed, using Stata, based on established statistical and economic 
methods, including the Human Capital Method. Open-ended questions will be analysed thematically. 
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Consent to participate will be sought from TB Fast Track participants who are being seen for their 6-
month study visit, using the participant information sheet and informed consent form provided.  
 
This sub-study will be led by a Masters' student studying health economics, supervised by the 
investigators. 
 
 
5. Data management 
 
5.1 Data management responsibilities 
 Oversee and coordinate the management of data; 
 Provide training and guidance to staff with respect to data management issues; 
 Oversee data quality control, including running data queries;  
 Ensure the availability of databases to capture data from participant interview and case note 
abstraction from medical records; 
 Ensure the safekeeping of data and access control; 
 Ensure proper data management documentation is maintained; 
 Manage data reporting processes; 
 Manage integration of data from different sources; 
 Ensure processes are in place for backup and data recovery. 
 
5.2 Application and database 
A client/server architecture will be used.  The database and the capturing application will be 
developed using appropriate software.  Scheduled backups will be done on a daily, weekly and 
monthly basis. A password will be required to gain access to the Aurum Institute for Health Research 
network to access data.  Study staff will be trained to generate reports from the application.  When 
data sets are generated for data analysis, personal identifiers will be removed. 
 
5.3 Quality control 
Data will be validated on entry, using range and consistency checks. Quality control procedures will 
include review of case report forms (CRFs) for completion and correctness.  Logical data checks will 
also be performed on the data. Incomplete and incorrect data queries will be sent back to sites 
electronically for error resolution. Errors will be reviewed and corrected on a weekly basis. The study 
will be monitored by internal monitors.  
 
Study records (consent forms, CRFs, screening logs) will be kept in a secure location accessible only 
to authorised study staff, investigators, and monitors. All records will be archived in a secure storage 
facility for at least ten years after the completion of the study. 
 
 
6. Statistical considerations 
6.1 Sample size estimation 
In our ART programme, mortality in the first 6 months after ART start among those with a baseline 
CD4<150 was 24/100 person years (pyrs);28 however, ascertainment of deaths did not include a 
search of national death registrations, and thus this is a minimum estimate of on-ART mortality. Our 
study cohort will be recruited at the point of assessment for ART, some weeks before ART would be 
routinely started; pre-ART mortality exceeds on-ART mortality,2 and 6-month mortality in the study 
cohorts, recruited at ART assessment, will therefore exceed observed on-ART mortality. We assume 
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that TB accounts for 60% of early deaths among patients initiating ART in South Africa; we 
hypothesise that, by earlier initiation of TB treatment, 66% of these could be averted. In addition, we 
estimate (based on our TB screening study, outlined above, section 2) that our strategy will result in 
ART being initiated in the intervention arm, on average, 2 months earlier than in the standard of 
care arm. Analyses of our ART programme data suggest that, among individuals with baseline CD4 
100-150 cells/μl, a 2 month delay in ART initiation results in a 150% increase in mortality by 6 
months (from 7% if ART is initiated immediately to 18% if there is a 2-month delay).39 Clearly, there 
must be overlap of preventable deaths between these two estimates, which we cannot determine 
precisely. It is also possible that some individuals who start TB treatment as part of the study may 
elect to discontinue it, which could reduce the magnitude of the intervention effect. Overall, we 
assume, conservatively, that the intervention will result in a 40% reduction in mortality by 6 months 
after study enrolment. 
 
Assuming 10 clusters per arm, 175 patients per cluster, 5% individuals whose vital status cannot be 
ascertained at 6 months, mortality estimated conservatively at 25/100 pyrs in the standard of care 
arm and taking account of the clustered design,40 using between-cluster coefficients of variation of 
0.2 and 0.25, there will be 91% and 85% power to assess 40% reduction in mortality, respectively. If 
the coefficient of variation is 0.2 there will be 81% power to assess 35% reduction in mortality.  
 
Note added to protocol version 5.0, 31 August 2013: we propose to extend enrolment to four 
additional clinics, in order to assure adequate study power despite slower than anticipated 
enrolment at some clinics. Assuming 12 clusters per arm, an harmonic mean of 109 participants per 
cluster, with other assumptions unchanged, using between-cluster coefficients of variation of 0.2 
and 0.25, there will be 90% and 84% power to assess 40% reduction in mortality, respectively. If the 
coefficient of variation is 0.2, there will be 80% power to assess 35% reduction in mortality. 
 
Note added to protocol version 6.1, 30 January 2015: enrolment was extended to a target harmonic 
mean of 117 participants per cluster, to be conservative with respect to the proportion of individuals 
whose vital status cannot be ascertained at 6 months. 
 
6.2 Statistical analysis  
Analyses will use methods appropriate for the clustered randomised trial design, giving each cluster 
equal weight. Quantitative outcomes will be summarised as the mean for each cluster and the 
difference of means for intervention vs. standard of care arm.  For binary outcomes or rate 
outcomes the overall risk (rate) for each cluster will be calculated, and the ratio for intervention vs. 
standard of care arm. The standard error for each effect measure will take into account stratified 
randomisation. An adjusted analysis will be conducted to help reduce variability across clinics with 
respect to primary and secondary outcomes and, after visual inspection, if imbalance across study 
arm of patient or clinic level factors is observed.40 In a supplementary analysis restricted to 
intervention clusters, we will assess for trends in the primary outcome across levels of success of 
implementing the intervention. A detailed analysis plan will be finalised prior to the end of data 
collection. 
 
Subgroup analyses will be conducted for the primary outcome for baseline CD4 count (<50, ≥50) and 
previous TB history (from self-report; no previous TB, previous TB).  
 
Given the relatively short recruitment period, and primary outcome measured at 6 months, we do 
not anticipate being able to perform a valid interim analysis. However, the Data Monitoring 
Committee will review the protocol and analysis plan and we will take further advice from them on 
this issue. 
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7. Protection of human participants 
This study will be conducted according to Good Clinical Practice (GCP) guidelines, in accordance with 
requirements of the funders and approving ethics committees.  
 
7.1 Regulatory approvals 
Approval will be sought from the Research Ethics Committees of the University of Witwatersrand 
and the London School of Hygiene and Tropical Medicine, UK. The study has been discussed with and 
has the support of senior staff responsible for tuberculosis control in the National Department of 
Health. Approval from relevant Provincial Research Committees will be obtained, and the protocol 
will be submitted to the South African Medicines Control Council for approval as a phase 4 clinical 
trial. 
 
The London School of Hygiene & Tropical Medicine will act as the main sponsor for this study. 
Delegated responsibilities will be assigned locally. London School of Hygiene & Tropical Medicine 
holds Public Liability ("negligent harm") and Clinical Trial ("non-negligent harm") insurance policies 
which apply to this trial.  
 
This trial will adhere to the principles outlined in the International Conference on Harmonisation 
Good Clinical Practice (ICH GCP) guidelines, protocol and all applicable local regulations. 
 
The study may be subject to audit by the London School of Hygiene & Tropical Medicine under their 
remit as sponsor, and inspection by regulatory authorities, to ensure compliance to the 
protocol, Good Clinical Practice and all applicable regulatory requirements. 
 
7.2 Risks and benefits for participants 
7.2.1 Risks and benefits 
Due to anticipated imperfect specificity of the algorithm, some individuals who do not have active 
TB, as defined by standard diagnostic methods, will receive TB treatment that they would not 
otherwise have received, with attendant risks, particularly of drug toxicities and drug interactions. 
However, BMI<18.5 and low haemoglobin identify individuals at high risk of active TB within the first 
six months on ART25 and these individuals are very likely to benefit from immediate TB treatment, in 
terms of a lower risk of incident TB and death. Individuals with latent TB will also benefit, by 
receiving treatment which will adequately treat their latent infection and thus reduce the future risk 
of active TB resulting from reactivation of latent infection. By circumventing the delays to ART 
initiation associated with traditional investigation pathways for smear-negative TB, we anticipate 
that time to ART in the intervention arm will be much shorter overall. We anticipate that the risk of 
serious manifestations of immune reconstitution syndrome will be lower in those with active TB who 
start TB treatment prior to ART, as compared with no TB treatment. We will monitor safety by 
reviewing available data concerning likely cause of death among all study participants, and by 
monitoring study-defined adverse events in the intervention arm (as a secondary outcome). 
 
Participants, both in intervention and control arms, will receive ZAR150 if they attend for a study 
review visit 6 months after enrolment, as compensation for their time and travel expenses. They will 
not be given any payment at the enrolment visit since this will be at the time of a clinic visit, 
although we may offer refreshments, particularly if participation results in increased time in clinic. 
Participants in the intervention arm who start TB treatment may be reviewed after 2 months to 
check that their treatment is appropriate; this will coincide with a routine clinic visit and will not be 
compensated.  We may contact participants, by cell phone if possible, periodically during the study 
to confirm contact details, and may offer cell phone airtime of small value (around R12) when 
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contact details are confirmed. If confirmation of contact details requires the participant to travel 
specifically for study purposes then travel expenses will be reimbursed at a level reflecting 
anticipated travel costs (around R20).  
 
7.3 Consent  
Clinic participation 
Participation of clinics will be by the consent of senior staff and managers. 
 
Individual participation 
Informed consent will be sought from potential participants using information sheets available in 
relevant languages (such as Sepedi, isiZulu, Xitsonga, English - appendix 3). Written informed 
consent will be sought, with the assistance of a translator where necessary, using standard consent 
forms. Participants unable to read or write will be asked to make a mark or thumbprint in the 
presence of a witness.  
 
7.4 Confidentiality 
All study records will be managed in a secure and confidential fashion. All records will be stored at 
the participating clinics and offices at provincial level in locked filing cabinets and access to the 
records will be restricted to specified study team members. Case report forms will be identified 
using the participant’s study number only, with locator information stored separately.   
 
7.5 Study discontinuation 
The study may be discontinued at any time by the funder, the trial steering committee, or by any of 
the relevant regulatory bodies. 
 
8. Trial governance and management 
 
8.1 Trial steering committee 
The trial steering committee will oversee the trial, monitoring its progress and receiving reports from 
the Data Monitoring Committee. The Trial Steering Committee will advise the Chief Investigator (CI) 
and investigator team, and will report to the trial funder and sponsor. 
 
Membership of the trial steering committee (as of September 2012) includes Prof Bertel Squire, 
Liverpool School of Tropical Medicine and President, International Union Against Tuberculosis 
(chair); Dr Lindiwe Mvusi, Director, DOTS Strategy Coordination, South African Department of 
Health; Bonginkosi Mthembu, Treatment Action Campaign; Dr Harry Hausler, Director, TB/HIV Care 
Association, South Africa; Prof Francois Venter, Wits Reproductive Health and HIV Institute, along 
with Prof. Grant (CI) and Dr Charalambous (PI for South Africa) and other investigators as needed. 
 
8.2 Trial investigator team 
The trial will be led by Prof. Alison Grant (CI; epidemiologist and HIV/infectious diseases specialist 
physician, LSHTM), in close collaboration with Dr Salome Charalambous (co-PI; Director of Research, 
Aurum Institute) and Dr Mpho Tlali (Trial Manager).  Dr Katherine Fielding (LSHTM) is the trial senior 
statistician, also overseeing data management. Dr Anna Vassall (health economist, LSHTM) will be 
responsible for the economic components of the study, supervising an SA-based junior economist. 
At Aurum Institute Dr Christopher Hoffmann (infectious diseases physician / epidemiologist, Director 
of ART programme) will provide clinical and epidemiological support, and Prof. Gavin Churchyard 
(Chief Executive Officer) senior managerial support.  
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Lead investigator for Foundation for Professional Development will be Suzanne Johnson (Head of 
Strategic Information); she will provide senior support at their collaborating sites. Dr Susan Dorman 
(Johns Hopkins University) will advise on diagnostics issues.  
 
LSHTM and Aurum Institute have had a highly productive collaboration since 1998: major projects 
include a cluster-randomised trial of community-wide tuberculosis preventive therapy in gold mines 
(80,000 participants in 15 clusters over 3 South African provinces; PI: Churchyard, co-PIs: Fielding 
and Grant) with nested projects on new TB diagnostics (Dorman) including cost-effectiveness; and 
development and evaluation of a multisite HIV care programme with over 18,000 patients, including 
studies of screening for tuberculosis among people with HIV (Charalambous, Churchyard, Hoffman, 
Fielding, Grant). Vassall brings to the team particular expertise in economic evaluation of new TB 
diagnostics which will be invaluable in assessing the cost and cost-effectiveness of this strategy, 
important to guide policy based on the results of the study. 
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Figure 1: Organisational chart: trial governance and senior management 
 
 
 
 
 
8.3 Trial operations team 
A full-time trial manager will lead the operational team, directed by the investigator team. Three 
regional co-ordinators will oversee field activities. The senior statistician and data manager will 
oversee all aspects of study data management. The operational team will meet by phone or in 
person weekly, and senior operational staff will meet the core investigator team at least monthly 
(more frequently during trial preparation and initiation). Clinical decision making will remain with 
the primary care team wherever possible, but clinically-qualified senior team members will be 
available to discuss any clinical problems. Data management is described in section 5, above.  
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8.4 Data Monitoring Committee 
The Data Monitoring Committee will monitor study data and make recommendations to the Trial 
Steering Committee concerning whether there are any safety reasons why the study should not 
continue. 
 
Figure 2: Organisational chart, trial operations team 
 
 
 
 
  
 
 
 
 
 
 
8.5 Trial registration 
The trial has been registered as a clinical trial (ISRCTN35344604; DOH-27-0812-3902 [South Africa]) 
and will be registered on the South African National Health Research Database. 
 
9. Logistics 
9.1 Timeline 
 Y1 (2012) Y2 (2013) Y3 (2014) 
 q1 q2 q3 q4 q1 q2 q3 q4 q1 q2 q3 q4 
Preparation             
Recruitment             
Follow up             
Analysis/write-up             
 
10. Publication policy 
Local stakeholders will be kept updated with trial progress. The research findings will be presented 
first to national stakeholders, and disseminated to stakeholders and participants in each province by 
means of local meetings. The results will be written up as one or more articles for submission to a 
suitable scientific journal.  
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Appendix 1: Study algorithm 
 
HIV+ adult presenting for ART 
Review with CD4 result 
 
CD4 >150; 
exclusions 
 
ineligible: follow 
routine procedures 
 
Study enrolment 
TB symptom screen 
Determine BMI; Hb; urine LAM 
Assess TB probability 
Sputum #1 for culture (study 
purposes) 
High probability TB 
any of: LAM positive, Hb<10; 
BMI<18.5 [or smear/GXP pos]  
Medium probability TB 
(symptomatic, Hb>10, 
BMI>18.5, LAM negative) 
Start antibiotics 
Request CXR 
Routine sputum smear / culture 
 
Review after 1 week 
symptoms, CXR, 
smear/GXP 
Low probability TB 
based on symptoms,  
smear/GXP, CXR 
High probability TB 
based on symptoms, 
smear/GXP, CXR 
BMI: body mass index 
CXR: chest radiograph 
GXP: Xpert MTB/RIF 
Hb: haemoglobin 
 
6 month post enrolment review (pt/notes) 
[if DNA, trace pt / designated contact  
check vs. national vital status records] 
continue ART 
 
Start ART 
 
 
 
Start TB treatment 
±2 week review 
if stable on TB 
treatment, start ART 
Low probability TB 
no symptoms, Hb>10, BMI>18.5, 
LAM negative 
2 month notes review 
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Appendix 2: Classification of adverse events 
We will use the Division of AIDS classification of adverse events, as revised in 2004 with clarifications in 
2009 (available at: http://rcc.tech-res-intl.com). Relevant sections are reproduced below: 
PARAMETER GRADE 1 
MILD 
GRADE 2 
MODERATE 
GRADE 3 
SEVERE 
GRADE 4 
POTENTIALLY 
LIFE-THREATENING 
Liver enzymes (LFT)     
AST (SGOT) 1.25–2.5 x ULN 2.6–5.0 x ULN 5.1–10.0 x ULN >10.0 x ULN 
ALT (SGPT) 1.25–2.5 x ULN 2.6–5.0 x ULN 5.1–10.0 x ULN >10.0 x ULN 
Bilirubin (total) 1.1–1.5 x ULN 1.6–2.5 x ULN 2.6–5.0 x ULN >5.0 x ULN 
Cutaneous     
Cutaneous reaction - rash Localized macular 
rash 
Diffuse macular,  
maculopapular, or 
morbiliform rash 
OR target lesions 
Diffuse macular,  
maculopapular, or 
morbiliform rash with 
vesicles or limited 
number of bullae OR 
superficial ulcerations 
of mucous membranes 
limited to one site 
Extensive or generalised 
bullous lesions OR 
Stevens Johnson 
syndrome OR ulceration 
of mucous membrane 
involving two or more 
distinct mucosal sites 
OR toxic epidermal 
necrolysis (TEN) 
Neurological     
Neurosensory alteration 
(including paresthesia and 
painful neuropathy) 
Asymptomatic with 
sensory alteration 
on exam, or 
minimal paresthesia 
causing no or 
minimal 
interference with 
usual social & 
functional activities 
Sensory alteration 
or paresthesia 
causing greater 
than minimal 
interference with 
usual social & 
functional activities 
Sensory alteration or 
paresthesia causing 
inability to perform 
usual social & 
functional activities 
Disabling sensory 
alteration or paresthesia 
causing inability to 
perform basic self-care 
functions 
Gastrointestinal     
Nausea Transient (<24hrs) 
or intermittent 
nausea with no or 
minimal 
interference with 
oral intake 
Persistent nausea 
resulting in 
decreased oral 
intake for 24-48 
hours 
Persistent nausea 
resulting in decreased 
oral intake for >48 
hours OR aggressive 
rehydration indicated 
(e.g. IV fluids) 
Life-threatening 
consequences (e.g. 
hypotensive shock) 
Vomiting Transient or 
intermittent 
vomiting with no or 
minimal 
interference with 
oral intake 
Frequent episodes 
of vomiting with 
mild or no 
dehydration 
Persistent vomiting 
resulting in orthostatic 
hypotension OR 
aggressive rehydration 
indicated (e.g. IV 
fluids) 
Life-threatening 
consequences (e.g. 
hypotensive shock) 
Nephrotoxicity     
Creatinine 1.1-1.3xULN 1.4-1.8xULN 1.9-3.4xULN ≥3.5xULN 
Visual      
Visual changes (from 
baseline) 
Visual changes 
causing no or 
minimal 
interference with 
usual social and 
functional activities 
Visual changes 
causing greater 
than minimal 
interference with 
usual social and 
functional activities 
Visual changes causing 
inability to perform 
usual social and 
functional activities 
Disabling visual loss in 
affected eye(s) 
Other clinical event not 
specified above 
Symptoms causing 
no or minimal 
interference with 
usual social and 
functional activities 
Symptoms causing 
greater than 
minimal 
interference with 
usual social and 
functional activities 
Symptoms causing 
inability to perform 
usual social and 
functional activities 
Symptoms causing 
inability to perform 
basic self-care functions; 
OR Medical or operative 
intervention indicated 
to prevent permanent 
impairment, persistent 
disability or death 
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Definition of descriptions of relationship of adverse event to study agent 
Classification Description 
Not associated The adverse event is clearly explained by another cause not 
related to the study agent. 
 
Probably not associated The adverse event is more likely explained by another cause 
than by the study agent 
Associated: possible The adverse event and administration of study agent are 
reasonably related in time, and the adverse event can be 
explained equally well by causes other than study agent. 
Associated: probable The adverse event and administration of study agent are 
reasonably related in time, and the adverse event is more 
likely explained by study agent than other causes. 
Associated: definite The adverse event and administration of study agent are 
related in time, and a direct association can be 
demonstrated. 
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Appendix 3: Participant information sheets and consent forms 
 
 
[these have been updated and are now presented in a separate document]
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Appendix 4: Case report forms 
[these have been updated and are now a separate document] 
